Please assess the completion status of the following clinical trial:

Trial Title: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age equal or greater than 60 years~2. Onset of symptoms \< 3 hours prior to randomisation~3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J point; scale: 1 mm per 0.1 mV):~   * ≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of ≥ 4 mm ST-elevation or~  * ≥ 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of ≥ 4 mm ST-elevation~4. Informed consent received~Exclusion Criteria:~1. 1. Expected performance of PCI \< 60 minutes from diagnosis (qualifying ECG) or inability to arrive at the catheterisation laboratory within 3 hours~2. Previous CABG~3. Left bundle branch block or ventricular pacing~4. Patients with cardiogenic shock - Killip Class 4~5. Patients with a body weight \< 55 kg (known or estimated)~6. Uncontrolled hypertension, defined as sustained blood pressure ≥ 180/110 mm Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to randomisation~7. Known prior stroke or TIA~8. Recent administration of any i.v. or s.c. anticoagulation within 12 hours, including unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral anticoagulation (i.e. warfarin or a NOACs)~9. Active bleeding or known bleeding disorder/diathesis~10. Known history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \< 3 months)~11. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction)~12. Clinical diagnosis associated with increased risk of bleeding including known active peptic ulceration and/or neoplasm with increased bleeding risk~13. Prolonged cardiopulmonary resuscitation (\> 2 minutes) within the past 2 weeks~14. Known acute pericarditis and/or subacute bacterial endocarditis~15. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis~16. Dementia~17. Known severe renal insufficiency~18. Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days~19. Known allergic reactions to tenecteplase, clopidogrel, enoxaparin and aspirin~20. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmaco-invasive strategy (Type: EXPERIMENTAL): Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
- Standard primary PCI (Type: ACTIVE_COMPARATOR): Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.

Based on this trial design, predict the completion outcome and termination type (if applicable).